Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by StockNews.com to “Strong-Buy”

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Monday.

A number of other research firms have also weighed in on REGN. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Argus upped their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Finally, Barclays upped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,097.05.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $10.91 during midday trading on Monday, hitting $1,071.28. 619,442 shares of the company’s stock were exchanged, compared to its average volume of 471,509. Regeneron Pharmaceuticals has a 12-month low of $765.28 and a 12-month high of $1,115.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96. The stock has a market cap of $118.04 billion, a price-to-earnings ratio of 31.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.13. The firm’s 50 day simple moving average is $1,043.43 and its 200 day simple moving average is $983.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.79 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals will post 37.38 EPS for the current year.

Insider Buying and Selling

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares in the company, valued at approximately $399,729,850. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,074 shares of company stock worth $64,546,123. Company insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. West Paces Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $28,000. Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. Finally, Family Firm Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.